Manufacturing The strategic investments expanding CDMO capabilities for HPAPIs and ADCs Pharmaceutical TechnologyDemand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Demand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology. Read full story Post navigation Previous: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remediesNext: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026